- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04553523
Hydrus® Microstent New Enrollment Post-Approval Study (CONFIRM)
September 20, 2023 updated by: Alcon Research
The Hydrus® Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm, Clinical Trial
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation.
Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Qualified subjects will attend a screening visit, a surgical visit (Day 0), and 8 scheduled postoperative visits at Day 1, Day 7, Month 1, Month 3, Month 6, Month 12, Month 18, and Month 24.
This study was initiated by Ivantis, Inc. Ivantis was acquired by Alcon Research, and Alcon assumed sponsorship of the study in November 2022.
Study Type
Interventional
Enrollment (Estimated)
545
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alcon Call Center
- Phone Number: 1-888-451-3937
- Email: alcon.medinfo@alcon.com
Study Locations
-
-
California
-
Irvine, California, United States, 92618
- Completed
- Coastal Vision
-
Sacramento, California, United States, 95815
- Recruiting
- Sacramento Eye Consultants
-
-
Colorado
-
Loveland, Colorado, United States, 80538
- Recruiting
- Eye Center of Northern Colorado
-
-
Iowa
-
Sioux City, Iowa, United States, 51104
- Recruiting
- Jones Eye Center PC
-
-
Kansas
-
Overland Park, Kansas, United States, 66213
- Not yet recruiting
- Stiles Eyecare Excellence Cataracts and Glaucoma
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- Not yet recruiting
- Visionary Eye Doctors
-
-
Michigan
-
Fraser, Michigan, United States, 48026
- Recruiting
- Fraser Eye Care Center
-
-
Minnesota
-
Coon Rapids, Minnesota, United States, 55433
- Recruiting
- Twin Cities Eye Consultants
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Recruiting
- Midwest Vision Research Foundation
-
Kansas City, Missouri, United States, 64154
- Not yet recruiting
- Moyes Eye Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89145
- Recruiting
- Center for Sight
-
-
North Carolina
-
Southern Pines, North Carolina, United States, 28387
- Recruiting
- Carolina Eye Associates PA
-
-
Ohio
-
Brecksville, Ohio, United States, 44141
- Completed
- Cleveland Eye Clinic
-
Cincinnati, Ohio, United States, 45242
- Recruiting
- Cincinnati Eye Institute
-
Mason, Ohio, United States, 45040
- Not yet recruiting
- Cincinnati Eye / Apex Eye
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066
- Not yet recruiting
- Scott & Christie and Associates, PC
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- Texan Eye / Keystone Research
-
Dallas, Texas, United States, 75231
- Not yet recruiting
- Glaucoma Associates of Texas
-
El Paso, Texas, United States, 79902
- Recruiting
- El Paso Eye Surgeons
-
Hurst, Texas, United States, 76054
- Recruiting
- Texas Eye Research Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Not yet recruiting
- The Eye Institute of Utah
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53142
- Recruiting
- Eye Centers of Racine and Kenosha
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- An operable, age-related cataract with best corrected visual acuity (BCVA) of 20/40 or worse;
- Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications;
- Optic nerve appearance characteristic of glaucoma;
- Medicated IOP less than or equal to 31 millimeters mercury (mmHg); Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Closed angle forms of glaucoma;
- Congenital or developmental glaucoma;
- Secondary glaucoma;
- Use of more than 4 ocular hypotensive medications;
- Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery;
- Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal;
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hydrus Microstent
Hydrus Microstent implanted in the eye immediately following cataract surgery and placement of a monofocal intraocular lens (IOL)
|
Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor.
The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
Cataract surgery performed using standard anesthesia and phacoemulsification techniques
Commercially available monofocal intraocular lens as determined by the investigator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of occurrence of clinically significant device malposition associated with clinical sequelae
Time Frame: Day 0 operative, up to Month 24 postoperative
|
The position of the implant will be assessed visually intraoperatively and at each postoperative follow-up visit.
Examples of clinically significant device malposition associated with clinical sequelae as listed in the protocol include secondary surgical intervention to modify device position or to remove the device (explantation), corneal endothelial touch by device, iris touch by the device associated with intraocular inflammation, pigment dispersion or other sequelae, central endothelial cell loss ≥30 percent, compromised corneal function, best-corrected visual acuity (BCVA) loss of 2 lines (10 letters) or more on the ETDRS chart, device obstruction requiring secondary surgical intervention, persistent anterior chamber inflammation with peripheral anterior synechiae, persistent anterior chamber inflammation without peripheral anterior synechiae, and chronic pain.
|
Day 0 operative, up to Month 24 postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of occurrence of intraoperative ocular adverse events
Time Frame: Day 0 operative
|
Intraoperative ocular adverse events as specified in the protocol include hyphema obscuring the surgeon's view, choroidal hemorrhage or effusion, choroidal detachment, significant iris injury or trauma, corneal abrasion, corneal edema, zonular dialysis, cyclodialysis, cyclodialysis cleft, iridodialysis, vitreous loss not associated with the cataract procedure, inadvertent perforation of the sclera, and Descemet's membrane detachment.
|
Day 0 operative
|
Rate of occurrence of sight threatening postoperative adverse events
Time Frame: Up to Month 24
|
Sight threatening, post-operative adverse events as specified in the protocol include endophthalmitis, corneal decompensation, severe retinal detachment, severe choroidal hemorrhage, severe choroidal detachment, and aqueous misdirection.
|
Up to Month 24
|
Rate of occurrence of other postoperative ocular adverse events
Time Frame: Up to Month 24
|
Other postoperative ocular adverse events as specified in the protocol include anterior uveitis/iritis, non-persistent & persistent, best corrected visual acuity (BCVA) loss of 2 lines or more, chronic pain, device migration, device obstruction, peripheral anterior synechiae (PAS), ocular secondary surgical interventions for intraocular pressure (IOP) or glaucoma management, hypotony at or after 1 month postop, hyphema, corneal opacification, corneal edema persisting or severe corneal edema, other retinal complications, elevated mean IOP >/=10 millimeters mercury (mmHg) vs screening, iris prolapse/wound incarceration, significant foreign body sensation at or after 3 months postop, surgical re-intervention, and worsening of visual field.
|
Up to Month 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Project Lead, CDMA Surgical, Alcon Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 25, 2020
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Study Registration Dates
First Submitted
September 11, 2020
First Submitted That Met QC Criteria
September 11, 2020
First Posted (Actual)
September 17, 2020
Study Record Updates
Last Update Posted (Actual)
September 22, 2023
Last Update Submitted That Met QC Criteria
September 20, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP 18-001
- GLI314-C003 (Other Identifier: Alcon Research)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open Angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
-
Glaucot Teknoloji Anonim SirketiRecruitingPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
Clinical Trials on Hydrus Microstent
-
[Redacted]WithheldPrimary Open Angle Glaucoma | Open Angle Glaucoma | Pseudoexfoliation Glaucoma | Pigmentary GlaucomaUnited States, Germany, Italy, Philippines, Spain, United Kingdom
-
InSight Vision Center Medical Group, IncRecruiting
-
Ridge Eye CareAlcon ResearchRecruitingGlaucoma, Open-AngleUnited States
-
Vold Vision P.L.L.CAlcon ResearchRecruitingGlaucoma, Open-Angle | CataractUnited States
-
Massachusetts Eye and Ear InfirmaryNot yet recruitingGlaucoma | Glaucoma, Open-Angle
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pseudoexfoliative Glaucoma | Pigmentary Dispersion GlaucomaUnited States
-
Asian Eye InstituteIvantis, Inc.CompletedPrimary Angle Closure Glaucoma | Primary Angle ClosurePhilippines
-
Diablo Eye AssociatesAlcon ResearchRecruitingOpen Angle GlaucomaUnited States
-
Ivantis, Inc.CompletedOpen-angle GlaucomaSpain, United States, United Kingdom, Philippines, Colombia